+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID06404528

Study of Low-Dose Chemotherapy During Controlled Low Blood Sugar for Treating Relapsed or Resistant Advanced Solid Tumors

Led by Wuxi People's Hospital · Updated on 2024-05-08

300

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of low-dose chemotherapy under controlled low blood sugar hypoglycemia to treat patients with relapsed refractory advanced solid tumors. This approach aims to activate the bodys innate immunity through necrotic tumor cells produced by chemotherapy, which may have strong anticancer effects without the usual toxic effects of chemotherapy. The treatment involves carefully managing patients blood sugar levels to create a hypoglycemic state while administering low doses of chemotherapy. This method is studied to assess its anticancer effects and minimize cytotoxic reactions. The study includes only one experimental group receiving this combined blood glucose control and chemotherapy treatment. Participants will be monitored for tumor relief over an average of one year, with additional follow-up to evaluate progression-free survival at three years and overall survival at five years. Assessments may include measuring tumor size based on specific criteria and monitoring overall health and side effects during treatment. The study period extends up to five years, allowing long-term observation of treatment outcomes and safety.

CONDITIONS

Brief Title

Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours

Research Team

P

Peihua Lu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here